Surprise Failure for Intra-Cellular Therapies’ Schizophrenia Drug Sends Shares Tumbling
Executive Summary
The unexpected failure of a Phase III trial of Intra-Cellular Therapies’ lead product ITI-007 sent shares in the company down by more than 63%.
You may also be interested in...
Reviva’s First Phase III Schizophrenia Readout Rivals Karuna’s Stellar KarXT
Small cap biopharma firm Reviva Pharmaceuticals reported intriguing Phase III results for its schizophrenia candidate brilaroxazine that are at least on par with Karuna’s closely watched drug.
Keeping Track Of The US FDA's Final Novel Approvals, CRLs Of 2019
The latest news on novel drug approvals and complete response letters from our US FDA Performance Tracker.
Intra-Cellular's Lumateperone Brings Mixed Results In Bipolar Depression
Firm will discuss Phase III data with the US FDA, calling results from a successful Phase III monotherapy study robust despite second Phase III study's failure. Lumateperone is under review for schizophrenia, with a 27 September action date.